New York, February 01, 2016 -- Moody's Investors Service placed Abbott Laboratories' A2 senior unsecured and Prime-1 short term ratings on review for downgrade. This follows the news that the company has signed a definitive agreement to acquire Alere, Inc. for $8.4 billion, including Alere's$2.6 billion of existing debt.

Vollständigen Artikel bei Moodys lesen